Quantum Biopharma Declares Completion of the Section 1 A number of Ascending Dose Medical Trial for its Experimental A number of Sclerosis Drug Lucid-21-302

Article content material

Security Overview Committee Discovered No Security Issues Following Milestone Trial

Article content material

Article content material

TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Firm”), right this moment introduced that it has accomplished its trial entitled “A Section 1, Randomised, Double-Blind, Placebo-Managed, A number of Ascending Dose Examine to Consider the Security and Pharmacokinetics of Lucid-21-302 in Wholesome Grownup Contributors.” A closing security overview committee (“SRC”) assembly was held after completion of the trial. The SRC discovered that Lucid-21-302 “(Lucid-MS”) was well-tolerated with no security considerations and no severe opposed occasions had been reported in the course of the trial.

Article content material

Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound for the remedy of a number of sclerosis (“MS”). It’s a patented New Chemical Entity (“NCE”) that has a singular mechanism of motion. As proven in preclinical fashions of MS, it might probably immediately stabilize the myelin sheath surrounding nerve fibers and thus present safety from demyelination. MS is a illness characterised by demyelination, a course of that causes progressive incapacity.

“Our scientific improvement workforce is thrilled that this Section 1 trial is now full, and that Lucid-MS was deemed protected and well-tolerated in wholesome members,” mentioned Dr. Andrzej Chruscinski, Vice-President, Scientific and Medical Affairs at Quantum Biopharma. “This marks an vital milestone and permits for the subsequent steps within the scientific improvement of Lucid-MS.”

Zeeshan Saeed, CEO of Quantum BioPharma added, “We’re enthusiastic about potential of Lucid-MS to guard myelin in MS sufferers because it represents a brand new path within the remedy of this illness. By finishing this trial and demonstrating security in wholesome members, we are actually nearer to initiating a Section 2 trial of Lucid-MS in individuals with MS.

Article content material

Article content material

“We are actually waiting for our Section 2 trial as we work in the direction of our targets of drug approval and commercialization of Lucid-MS. We sit up for offering additional updates as we execute on our milestones, pushed by our mission to arrest demyelination in MS,” concluded Saeed.

About Quantum BioPharma Ltd.

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical firm devoted to constructing a portfolio of revolutionary belongings and biotech options for the remedy of difficult neurodegenerative and metabolic issues and alcohol misuse issues with drug candidates in numerous phases of improvement. By means of its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is targeted on the analysis and improvement of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity proven to forestall and reverse myelin degradation, the underlying mechanism of a number of sclerosis, in preclinical fashions. Quantum BioPharma invented unbuzzd™ and spun out its OTC model to an organization, Celly Vitamin Corp. (“Celly Vitamin”), led by trade veterans. Quantum BioPharma retains possession of 25.71% (as of June 30, 2024) of Celly Vitamin at www.unbuzzd.com. The settlement with Celly Vitamin additionally contains royalty funds of seven% of gross sales from unbuzzd™ till funds to Quantum BioPharma complete $250 million. As soon as $250 million is reached, the royalty drops to three% in perpetuity. Quantum BioPharma retains 100% of the rights to develop related merchandise or different formulations particularly for pharmaceutical and medical makes use of. Quantum BioPharma maintains a portfolio of strategic investments via its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or industrial property. For extra data go to www.quantumbiopharma.com.

Article content material

Ahead Trying Data

This press launch accommodates sure “forward-looking statements” throughout the which means of relevant Canadian securities legislation. Any statements that categorical or contain discussions with respect to predictions, expectations, beliefs, plans, projections, targets, assumptions or future occasions or efficiency (usually, however not at all times, recognized by phrases or phrases similar to “believes”, “anticipates”, “expects”, “is predicted”, “scheduled”, “estimates”, “pending”, “intends”, “plans”, “forecasts”, “targets”, or “hopes”, or variations of such phrases and phrases or statements that sure actions, occasions or outcomes “might”, “may”, “would”, “will”, “ought to” “may”, “can be taken”, or “happen” and related expressions) aren’t statements of historic reality and could also be forward-looking statements. The forward-looking data and forward-looking statements contained herein embody, however aren’t restricted to, statements concerning: the Firm’s concentrate on the analysis and improvement of Lucid-MS to forestall and reverse myelin degradation; the Firm’s Lucid-21-302 scientific improvement program in a number of sclerosis advancing in the direction of human phase-2 efficacy trials; the Firm’s intention to retain 100% of the rights to develop merchandise for pharmaceutical and medical makes use of; the Firm’s intention to keep up a portfolio of strategic investments via FSD Strategic Investments Inc.; MZ enjoying a key function in aiding the Firm to reinforce its market consciousness and foster productive, persevering with dialogues with shareholders and different market members; MZ being engaged by the Firm for the MZ Preliminary Interval; MZ working with the Firm to develop and implement a complete capital markets technique designed to extend the Firm’s visibility all through the funding group; MZ marketing campaign highlighting how Quantum BioPharma is growing a strong pipeline of merchandise and belongings centered on addressing vital unmet wants in mind issues and alcohol well being; and the Firm’s method to therapies in mind issues and alcohol well being representing an incredible income potential.

Article content material

Ahead-looking data on this information launch are primarily based on sure assumptions and anticipated future occasions, specifically: the Firm’s evaluation of market circumstances, its capability to achieve market share, and its potential aggressive edge are correct; the Firm can have the power to hold out its plans with respect to its new innovation and choices, together with its capability to conduct analysis and improvement of Lucid-MS; the Firm’s Lucid-21-302 scientific improvement program in a number of sclerosis will advance in the direction of human phase-2 efficacy trials; the Firm will retain 100% of the rights to develop related product or different formulations particularly for pharmaceutical and medical makes use of; the Firm will search new enterprise alternatives; the Firm will improve effectivity in its processes and partnerships; the Firm can have the power to hold out its different targets and targets the Firm’s intention to keep up a portfolio of strategic investments via FSD Strategic Investments Inc.; MZ will play a key function in aiding the Firm to reinforce its market consciousness and foster productive, persevering with dialogues with shareholders and different market members; MZ can be engaged by the Firm for the MZ Preliminary Interval; MZ will work with the Firm to develop and implement a complete capital markets technique designed to extend the Firm’s visibility all through the funding group; the MZ marketing campaign will spotlight how Quantum BioPharma is growing a strong pipeline of merchandise and belongings centered on addressing vital unmet wants in mind issues and alcohol well being; and the Firm’s method to therapies in mind issues and alcohol well being can have an incredible income potential.

Article content material

These statements contain recognized and unknown dangers, uncertainties and different components, which can trigger precise outcomes, efficiency or achievements to vary materially from these expressed or implied by such statements, together with however not restricted to: the Firm’s lack of ability to retain 100% of the rights to develop merchandise for pharmaceutical or medical makes use of; the Firm’s lack of ability to reinforce its product improvement capabilities and/or preserve a portfolio of strategic investments; the Firm’s Lucid-21-302 scientific improvement program in a number of sclerosis not advancing in the direction of human phase-2 efficacy trials; the Firm won’t have the power to hold out its different targets and targets the Firm’s intention to keep up a portfolio of strategic investments via FSD Strategic Investments Inc.; MZ won’t play a key function in aiding the Firm to reinforce its market consciousness and foster productive, persevering with dialogues with shareholders and different market members; MZ won’t be engaged by the Firm for the MZ Preliminary Interval; MZ won’t work with the Firm to develop and implement a complete capital markets technique designed to extend the Firm’s visibility all through the funding group; the MZ marketing campaign won’t spotlight how Quantum BioPharma is growing a strong pipeline of merchandise and belongings centered on addressing vital unmet wants in mind issues and alcohol well being; the Firm’s method to therapies in mind issues and alcohol well being won’t have an incredible income potential; and the dangers mentioned within the Firm’s Annual Report on Kind 20-F for the fiscal 12 months ended December 31, 2023, closing quick type base shelf prospectus dated December 22, 2023 and registration assertion on Kind F-3 containing a base shelf prospectus, every beneath the heading “Threat Elements”. These components must be thought of rigorously, and readers shouldn’t place undue reliance on the forward-looking statements. Readers are cautioned that the foregoing checklist isn’t exhaustive. Though the forward-looking statements contained on this press launch are primarily based upon what administration believes to be cheap assumptions, the Firm can not guarantee readers that precise outcomes can be in line with these forward-looking statements. Ahead-looking statements contained on this information launch are expressly certified by this cautionary assertion and mirror the Firm’s expectations as of the date hereof and are topic to vary thereafter. The Firm undertakes no obligation to replace or revise any forward-looking statements, whether or not on account of new data, estimates or opinions, future occasions, or outcomes or in any other case or to clarify any materials distinction between subsequent precise occasions and such forward-looking data, besides as required by relevant legislation.

Article content material

The reader is urged to consult with extra data referring to Quantum BioPharma, together with its annual data type, will be positioned on the SEDAR+ web site at www.sedarplus.ca and on the EDGAR part of the USA Securities and Change Fee’s web site at www.sec.gov for a extra full dialogue of such threat components and their potential results.

Contacts:

Quantum BioPharma Ltd.

Zeeshan Saeed, Founder, CEO and Govt Co-Chairman of the Board
Electronic mail: Zsaeed@quantumbiopharma.com  
Phone: (833) 571-1811

Investor Relations

Chris Tyson
Govt Vice President
MZ North America
Direct: 949-491-8235
QNTM@mzgroup.us  
www.mzgroup.us  

Article content material